Johnson & Johnson's venture capital arm, one of the oldest corporate venture groups in healthcare. It invests alongside J&J's innovation centres and JLABS incubators, including in cancer companies.
JJDC, Inc. (Johnson & Johnson Development Corporation) is the venture capital arm of Johnson & Johnson Innovation. The Wikipedia entry for Johnson & Johnson Innovation states that the unit 'provides startups with sourcing, infrastructure, and capital equipment at JLABS, financing & venture capital at JJDC, Inc., and collaborations leading to the potential development of medical device technologies, pharmaceuticals, and therapeutics'. JJDC invests across pharmaceuticals, medical devices and consumer health at all stages, typically as a strategic minority investor. Its own web pages (jnjinnovation.com and jnj.com/innovation/jjdc) are JavaScript applications that returned no readable content or a maintenance error, so founding year, headquarters and named oncology portfolio companies could not be confirmed from a primary source.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Bright Peak Therapeutics Allschwil, CH | Growth stage | biotech | Series C 2024, $90M | |
| EpiBiologics San Mateo, CA, US | Growth stage | biotech | Non-small-cell lung cancerHead and neck squamous cell carcinoma | Series B 2026, $107M |
| Link Cell Therapies South San Francisco, CA, US | Startup | cell therapy | Clear cell renal cell carcinoma | Series A extension 2026, $30M |
| Mestag Therapeutics Cambridge, GB | Growth stage | biotech | Financing 2026, $40M | |
| On Target Laboratories West Lafayette, IN, US | Startup | imaging | Ovarian cancerNon-small-cell lung cancer | none on record |
| Rondo Therapeutics Hayward, CA, US | Growth stage | biotech | Bladder & urothelial cancerHead and neck squamous cell carcinomaNon-small-cell lung cancerCervical cancerTriple-negative breast cancer (TNBC) | Series A 2022, $67M |
| Stylus Medicine Cambridge, MA, US | Startup | biotech | Series A 2025, $85M |
Shares Mestag Therapeutics, EpiBiologics and the tag corporate-venture.
Shares EpiBiologics and the tag corporate-venture.
Shares Bright Peak Therapeutics and the tag corporate-venture.
Shares Mestag Therapeutics, Rondo Therapeutics.
Shares Link Cell Therapies, EpiBiologics.
Shares Stylus Medicine, Bright Peak Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/